FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2096568394> ?p ?o ?g. }

• W2096568394 endingPage "1259" @default.
• W2096568394 startingPage "1254" @default.
• W2096568394 abstract "Recent publications have indicated that the alpha/beta ratios for carcinoma of the prostate are much lower than had originally been thought, suggesting that prostate cancer may be highly sensitive to fraction size. We have reviewed our unique experience of the use of 3.13 Gy fractions in a large cohort of men treated homogeneously in a single institute.The outcome for 705 men with T1-T4, N0, M0 prostate cancer who received conformal radiotherapy between 1995 and 1998 at this center was analyzed. No patient received hormonal manipulation. Mean age was 68 years (range: 49-84 years). Median pretreatment PSA was 13 ng/mL (range: 0.6-270 ng/mL). Disease characteristics were as follows: Stage T1, 125 (18%); T2, 365 (52%); T3/4, 215 (30%); Gleason 2-6, 463 (66%); Gleason 7-10, 242 (34%); pretreatment PSA < or =10 ng/mL, 291 (41%); 10 to < or =20, 228 (32%); >20, 186 (27%). Median follow-up was 48 months (range: 1-82 months). Biochemical-free survival (bNED) was defined by the American Society for Therapeutic Radiology and Oncology consensus definition. Radiotherapy was delivered to a planning target volume (prostate plus all/base of the seminal vesicles dependent on risk criteria with a 1-cm margin) with a 4-field conformal technique to a dose of 50 Gy in 16 daily fractions over 22 days.The 5-year bNED survival was significantly associated (p < 0.001) with pretreatment PSA, stage, and Gleason score. Five-year bNED rates with respect to pretreatment characteristics were as follows: 73% (PSA < or =10), 52% (>10-20), 35% (>20), 64% (Stage T1/2), 38% (T3/4), 61% (Gleason score 2-6), and 46% (Gleason > or =7). When patients were grouped into good (Stage T1/2, PSA < or =10 ng/mL, and Gleason score <7) (n = 181), intermediate (1 raised value) (n = 247), or poor (2 or more raised values) (n = 277) prognostic groups, the bNED was, respectively, 82%, 56%, and 39%. Radiation Therapy Oncology Group Grade > or =2 bowel toxicity was 5% and bladder 9%.These data indicate that the delivery of a relatively low total dose using a hypofractionated regime results in similar tumor control and normal-tissue toxicity to 65-70 Gy delivered in 1.8-2 Gy fractions. These data suggest that this is an acceptable regime for good-prognosis patients. However, because of the evidence for a dose effect at doses above 70 Gy with conventional fractionation, we are now treating intermediate- and poor-risk patients within a hypofractionated dose escalation trial to 60 Gy in 20 fractions using intensity- modulated radiotherapy." @default.
• W2096568394 created "2016-06-24" @default.
• W2096568394 creator A5010055502 @default.
• W2096568394 creator A5029123237 @default.
• W2096568394 creator A5035054500 @default.
• W2096568394 creator A5054787753 @default.
• W2096568394 creator A5056060960 @default.
• W2096568394 creator A5080362183 @default.
• W2096568394 creator A5091827101 @default.
• W2096568394 date "2003-12-01" @default.
• W2096568394 modified "2023-10-14" @default.
• W2096568394 title "Hypofractionated conformal radiotherapy in carcinoma of the prostate: five-year outcome analysis" @default.
• W2096568394 cites W1868732334 @default.
• W2096568394 cites W1976578751 @default.
• W2096568394 cites W1978906140 @default.
• W2096568394 cites W1980789427 @default.
• W2096568394 cites W1983095373 @default.
• W2096568394 cites W1990510898 @default.
• W2096568394 cites W2001127718 @default.
• W2096568394 cites W2001141099 @default.
• W2096568394 cites W2021200503 @default.
• W2096568394 cites W2023801183 @default.
• W2096568394 cites W2023807811 @default.
• W2096568394 cites W2037920341 @default.
• W2096568394 cites W2043945205 @default.
• W2096568394 cites W2044032707 @default.
• W2096568394 cites W2054020299 @default.
• W2096568394 cites W2089403922 @default.
• W2096568394 cites W2090286083 @default.
• W2096568394 cites W2093485750 @default.
• W2096568394 cites W2104631398 @default.
• W2096568394 cites W2160149049 @default.
• W2096568394 cites W2163217542 @default.
• W2096568394 cites W4292806894 @default.
• W2096568394 doi "https://doi.org/10.1016/s0360-3016(03)00752-1" @default.
• W2096568394 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14630259" @default.
• W2096568394 hasPublicationYear "2003" @default.
• W2096568394 type Work @default.
• W2096568394 sameAs 2096568394 @default.
• W2096568394 citedByCount "141" @default.
• W2096568394 countsByYear W20965683942012 @default.
• W2096568394 countsByYear W20965683942013 @default.
• W2096568394 countsByYear W20965683942014 @default.
• W2096568394 countsByYear W20965683942015 @default.
• W2096568394 countsByYear W20965683942016 @default.
• W2096568394 countsByYear W20965683942017 @default.
• W2096568394 countsByYear W20965683942018 @default.
• W2096568394 countsByYear W20965683942019 @default.
• W2096568394 countsByYear W20965683942021 @default.
• W2096568394 crossrefType "journal-article" @default.
• W2096568394 hasAuthorship W2096568394A5010055502 @default.
• W2096568394 hasAuthorship W2096568394A5029123237 @default.
• W2096568394 hasAuthorship W2096568394A5035054500 @default.
• W2096568394 hasAuthorship W2096568394A5054787753 @default.
• W2096568394 hasAuthorship W2096568394A5056060960 @default.
• W2096568394 hasAuthorship W2096568394A5080362183 @default.
• W2096568394 hasAuthorship W2096568394A5091827101 @default.
• W2096568394 hasConcept C121608353 @default.
• W2096568394 hasConcept C126322002 @default.
• W2096568394 hasConcept C126894567 @default.
• W2096568394 hasConcept C146357865 @default.
• W2096568394 hasConcept C151730666 @default.
• W2096568394 hasConcept C2776235491 @default.
• W2096568394 hasConcept C2777546739 @default.
• W2096568394 hasConcept C2780192828 @default.
• W2096568394 hasConcept C2989005 @default.
• W2096568394 hasConcept C509974204 @default.
• W2096568394 hasConcept C71924100 @default.
• W2096568394 hasConcept C86803240 @default.
• W2096568394 hasConceptScore W2096568394C121608353 @default.
• W2096568394 hasConceptScore W2096568394C126322002 @default.
• W2096568394 hasConceptScore W2096568394C126894567 @default.
• W2096568394 hasConceptScore W2096568394C146357865 @default.
• W2096568394 hasConceptScore W2096568394C151730666 @default.
• W2096568394 hasConceptScore W2096568394C2776235491 @default.
• W2096568394 hasConceptScore W2096568394C2777546739 @default.
• W2096568394 hasConceptScore W2096568394C2780192828 @default.
• W2096568394 hasConceptScore W2096568394C2989005 @default.
• W2096568394 hasConceptScore W2096568394C509974204 @default.
• W2096568394 hasConceptScore W2096568394C71924100 @default.
• W2096568394 hasConceptScore W2096568394C86803240 @default.
• W2096568394 hasIssue "5" @default.
• W2096568394 hasLocation W20965683941 @default.
• W2096568394 hasLocation W20965683942 @default.
• W2096568394 hasOpenAccess W2096568394 @default.
• W2096568394 hasPrimaryLocation W20965683941 @default.
• W2096568394 hasRelatedWork W1980188241 @default.
• W2096568394 hasRelatedWork W1980245127 @default.
• W2096568394 hasRelatedWork W2038565121 @default.
• W2096568394 hasRelatedWork W2127440557 @default.
• W2096568394 hasRelatedWork W2362655045 @default.
• W2096568394 hasRelatedWork W2372081072 @default.
• W2096568394 hasRelatedWork W2590008096 @default.
• W2096568394 hasRelatedWork W2897445903 @default.
• W2096568394 hasRelatedWork W3082324229 @default.
• W2096568394 hasRelatedWork W3129209394 @default.
• W2096568394 hasVolume "57" @default.
• W2096568394 isParatext "false" @default.

• next